GigaMune Secures Collaboration with Mass General for Development of Cell Therapies for Cancer

Share Article

Research collaboration to identify novel anti-tumor T cell receptors for cell therapies for cancer

On June 13, 2018, GigaMune entered into a research collaboration with Massachusetts General Hospital (Mass General). The purpose of the collaboration is to use GigaMune's patented T cell receptor (TCR) discovery technology to identify therapeutic TCRs in healthy donor samples. The TCRs will be directed against novel shared tumor antigens that are expressed by solid tumors. The project will be led by Dr. Mark Cobbold, a translational immunologist and an expert in tumor antigens at Mass General, and Dr. David Johnson, Founder of GigaMune and expert in immune genomics. The financial terms of the agreement were not disclosed.

About GigaMune

GigaMune Inc. is a new cancer cell therapy company focused on T cell receptor (TCR) discovery and development. GigaMune was founded in 2017 as a spin-out from GigaGen, which is focused on discovery and development of therapeutic polyclonal and monoclonal antibodies. GigaMune's patented TCR technologies are an extension of GigaGen's industry-leading single cell immune repertoire technologies for antibody discovery. GigaMune's laboratory is located in South San Francisco, California.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Johnson
Visit website